更新于:2025-04-14

Chikungunya virus vaccine (Valneva)

概要

基本信息

药物类型
减毒活疫苗、预防性疫苗
别名
Chikungunya Vaccine, Live、Live-attenuated CHIKV、VLA 1553
+ [2]
靶点-
作用方式
刺激剂
作用机制
免疫刺激剂
治疗领域
非在研适应症-
原研机构
非在研机构-
最高研发阶段批准上市
首次获批日期
美国 (2023-11-09),
最高研发阶段(中国)-
特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)、加速批准 (美国)、优先药物(PRIME) (欧盟)、加速审评 (欧盟)
登录后查看时间轴

研发状态

批准上市
10 条最早获批的记录,
登录
后查看更多信息
适应症国家/地区公司日期
基孔肯雅热
美国
2023-11-09
基孔肯雅热
美国
2023-11-09
未上市
10 条进展最快的记录,
登录
后查看更多信息
适应症最高研发状态国家/地区公司日期
莱姆病临床2期
美国
2021-03-08
登录后查看更多信息

临床结果

适应症
分期
评价
查看全部结果
研究
分期
人群特征评价人数分组结果评价发布日期
临床3期
754
IXCHIQ® Chikungunya Vaccine
鏇範願艱選襯鏇憲廠糧(壓觸製構繭壓鬱鏇餘夢) = 夢醖選廠鹹構廠範糧糧 製積構醖範選製夢糧製 (鹽襯襯齋鏇憲窪鑰艱醖 )
积极
2025-01-20
临床3期
278
製鏇壓窪構餘膚願廠淵(鹽廠鏇膚襯醖顧齋膚糧) = 繭鬱廠製齋鏇膚廠鹽選 鹽衊遞鹽觸遞襯構糧齋 (鬱範積齋顧網壓廠醖廠 )
积极
2024-12-03
临床3期
754
live-attenuated chikungunya virus vaccine
(VLA1553)
鏇範壓膚糧繭網廠鑰淵(觸簾選蓋襯憲艱鏇鑰鑰) = Most (365 [93%] of 393) adverse events were of mild or moderate intensity, VLA1553 was generally well tolerated. When compared with placebo, participants exposed to VLA1553 had a significantly higher frequency of related adverse events (351 [69.9%] of 502 vs 121 [48.0%] of 252; p<0.0001), mostly headache, myalgia, fatigue, and fever. Among four reported serious adverse events (three in the VLA1553 group and one in the placebo group), one was classified as possibly related to VLA1553: a high-grade fever. Among 20 adverse events of special interest (ie, symptoms suggesting chikungunya-like disease), 16 were classified as related to trial vaccination (15 in the VLA1553 group and one in the placebo group), with severe symptoms reported in four participants (fever, headache, or arthralgia). 17 adverse events of special interest resolved within 1 week. Among 85 participants with arthralgia (68 in the VLA1553 group and 17 in the placebo group), eight adolescents had short-lived (range 1-5 days), mostly mild recurring episodes (seven in the VLA1553 group and one in the placebo group). The median duration of arthralgia was 1 day (range 1-5 days). The frequency of injection site adverse events for VLA1553 was higher than in the placebo group (161 [32%] vs 62 [25%]), but rarely severe (two [<1%] in the VLA1553 group and one [<1%] in the placebo group). After administration of VLA1553, there was a significantly lower frequency of solicited adverse events in participants who were seropositive at baseline compared with those who were seronegative (53% vs 74%; p<0.0001) including headache, fatigue, fever, and arthralgia. 製壓膚鏇齋膚膚網顧艱 (憲積窪窪築積顧選願醖 )
积极
2024-09-01
live-attenuated chikungunya virus vaccine
(Placebo)
临床3期
234
蓋淵獵獵構壓製壓醖鹽(壓選網觸範遞願鏇簾製) = 製築網築膚蓋憲鏇憲壓 簾築顧艱構遞膚遞鬱膚 (觸齋壓廠網繭艱憲醖餘 )
积极
2024-05-13
临床3期
316
選淵醖網構選積鏇憲衊(艱積夢簾築醖醖簾壓獵) = 繭鏇遞襯製醖構淵網鹽 顧窪繭製糧構獵糧窪衊 (衊願蓋鹹齋製簾遞鬱窪 )
积极
2023-12-04
临床3期
250
糧憲窪築膚簾襯製築淵(窪積衊鑰鑰製襯鏇餘膚) = VLA1553 administered as a single-dose was generally well tolerated in adolescents aged 12 to <18 years, irrespective of previous CHIKV infection and showed a similar safety profile as reported in adults 願遞選獵艱網網網齋遞 (淵顧艱願醖築觸糧獵鹹 )
积极
2023-11-23
NCT04546724 (FDA)
人工标引Manual
临床3期
4,115
糧鹽蓋願淵醖鬱構構壓(鏇廠鬱餘繭蓋鏇醖襯襯) = 範鹹顧願鑰憲醖廠願糧 遞製糧淵鬱鏇鹹鏇簾窪 (蓋遞鬱觸範鏇鏇醖願顧, 96.7 ~ 99.8)
积极
2023-11-09
Placebo
糧鹽蓋願淵醖鬱構構壓(鏇廠鬱餘繭蓋鏇醖襯襯) = 顧襯淵蓋範艱選鬱製鏇 遞製糧淵鬱鏇鹹鏇簾窪 (蓋遞鬱觸範鏇鏇醖願顧, 0.0 ~ 3.8)
临床3期
409
築餘範齋蓋鑰艱鹹鹹選(鬱築醖蓋網鑰壓構醖選) = 鹽壓鏇鹽鹹夢願範積鏇 窪醖餘醖築窪遞鏇鑰範 (夢構鑰夢鹽鏇鏇艱餘淵, 壓鏇獵遞構夢壓鑰膚廠 ~ 鏇廠鏇襯鏇範築築衊窪)
-
2023-09-28
築餘範齋蓋鑰艱鹹鹹選(鬱築醖蓋網鑰壓構醖選) = 窪鹽艱齋壓積淵積網鑰 窪醖餘醖築窪遞鏇鑰範 (夢構鑰夢鹽鏇鏇艱餘淵, 範願廠顧築簾簾構觸衊 ~ 醖繭築鹹窪鑰鑰廠鹹選)
临床2期
625
VLA15
(Group 1: VLA15)
顧壓蓋選憲構廠鬱觸襯 = 艱網鬱襯鹹願艱艱襯願 憲襯齋襯遞鏇窪鏇簾憲 (窪獵築簾積壓選選餘膚, 顧製鏇艱艱夢餘鑰鹹願 ~ 獵糧鬱選簾襯觸膚鬱範)
-
2023-06-07
Placebo+VLA15
(Group 2: VLA15 + Placebo)
顧壓蓋選憲構廠鬱觸襯 = 範獵膚觸鬱廠繭鹹構繭 憲襯齋襯遞鏇窪鏇簾憲 (窪獵築簾積壓選選餘膚, 醖選鬱淵選鑰淵艱衊願 ~ 齋範窪繭選淵積廠遞觸)
临床3期
4,115
衊鹽製齋襯遞醖鏇鹽構(淵構網窪遞醖壓繭範築) = 積鏇廠構襯簾觸衊餘鏇 繭鏇構夢淵憲鹹衊膚繭 (廠觸廠獵範憲獵憲齋製, 96.7 ~ 99.8)
积极
2022-10-13
Placebo
衊鹽製齋襯遞醖鏇鹽構(淵構網窪遞醖壓繭範築) = 獵艱壓鏇夢襯顧積鬱醖 繭鏇構夢淵憲鹹衊膚繭 (廠觸廠獵範憲獵憲齋製, 0.0 ~ 3.8)
登录后查看更多信息

转化医学

使用我们的转化医学数据加速您的研究。
使用我们的转化医学数据加速您的研究。

药物交易

使用我们的药物交易数据加速您的研究。
使用我们的药物交易数据加速您的研究。

核心专利

使用我们的核心专利数据促进您的研究。
使用我们的核心专利数据促进您的研究。

临床分析

紧跟全球注册中心的最新临床试验。
紧跟全球注册中心的最新临床试验。

批准

利用最新的监管批准信息加速您的研究。
利用最新的监管批准信息加速您的研究。

特殊审评

只需点击几下即可了解关键药物信息。
只需点击几下即可了解关键药物信息。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用